David Pritchard, CEO of KaloBios Pharmaceuticals Inc (KBIO), says the company is looking for partners for its KB001-A and KB004, which are both in Phase II clinical testing. KB001-A is targeted against a bacterium called Pseudomonas aeruginosa, and it has been studied for treatment for cystic fibrosis. KB004 is a humaneered antibody that is being studied for the treatment of acute myeloid leukemia, or AML; myelodysplastic syndromes, or MDS; and myelofibrosis.
“Partner selection indeed is very important in that you are trying through partnering to accelerate your program and move it forward,” Pritchard says. “In my experience, small companies often tend to move more quickly in their early stages. However, when you get past proof of concept, I think bigger companies can — particularly on a global basis — often conduct large pivotal studies, approvals, launches and reimbursement programs better than small companies, in light of their experience and resources.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Pritchard says KaloBios is seeking partners for KB001-A particularly for hospital-associated infections, such as the ventilator-assisted pneumonia area and outside of the United States for cystic fibrosis.
“In the cancer program, we are seeking partners who could help us expand the development of KB004 into solid tumors as well as different geographies,” Pritchard says. “For that product, we envision a side-by-side co-development-type program where we could imagine focusing on different indications between ourselves and the partner, and equally sharing the benefits.”
Two Harbors Investment Corp. (TWO) Exposed to Nonagency RMBS; Hybrid REITs Tied to Macro Improvement
June 18, 2013
Two Harbors Investment Corp (NYSE:TWO) Grows Book Value and Diversifies Asset Base
June 27, 2013
Two Harbors Investment Corp (TWO) a Pioneer Within Mortgage REIT Industry
July 02, 2014
Vertex Pharmaceuticals Incorporation (VRTX) Has High Success Levels with Novel Cystic Fibrosis Drugs
November 24, 2014
Gilead Sciences, Inc. (GILD) Leading the Charge in Hepatitis C Space with Shorter-Duration Drugs
April 26, 2013
